Zoll Medical said this week it won approval from Health Canada for its Zoll AED 3 and Zoll AED 3 BLS automated external defibrillators and launched them in the region.
Both newly-cleared AEDs provide real-time feedback to communicate appropriate timing for effective CPR through audible and visual prompts, which the Chelmsford, Mass.-based company said can be critical to a patient’s survival.
“We are extremely excited to add the Zoll AED 3 and the Zoll AED 3 BLS to our portfolio of automated external defibrillators. With the addition of these new devices, we are able to offer our public access and BLS customers an even more comprehensive line of AEDs and the latest tools to better manage their AEDs’ readiness and access to clinical event data,” Zoll resuscitation division prez A. Whiton said in a prepared statement.
Zoll said that both devices are cleared for use on adult and pediatric patients, and include the capability for remote monitoring to maintain that the devices are ready for use.
“This next generation of AEDs enhances Zoll’s portfolio of top-of-the-line defibrillators by continuing to improve real-time CPR feedback and providing even better support for rescuers. We are pleased to make these lifesaving devices available to both lay and professional rescuers in Canada. Estimates indicate there are at least 1 million deaths globally each year from sudden cardiac arrest. In Canada, the annual number of such deaths is approximately 40,000. We are proud to offer products that can help save lives,” Zoll marketing VP Elijah White said in a press release.
Earlier this month, Zoll Medical said it won FDA premarket approval for its Hospital Wearable Defibrillator. The company’s HWD is designed to continuously protect patients at risk of ventricular tachycardia or ventricular fibrillation during hospital stays. The wearable device is designed to automatically detect and treat such events.